Trial Profile
Analysis of genetic polymorphism relating to interstitial lung disease events in patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Adenosquamous carcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacogenomic
- 03 Oct 2018 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 05 Oct 2012 New trial record